Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA.
JAMA Surg. 2013 May;148(5):419-26. doi: 10.1001/jamasurg.2013.173.
There is a scarcity of research on immunocompromised patients with necrotizing soft-tissue infection (NSTI).
To evaluate the effect of immunocompromised status in patients with NSTI.
Single-institution retrospective cohort study at a tertiary academic teaching hospital affiliated with a major cancer center.
Patients with NSTI.
Treatment at Brigham and Women's Hospital and Dana-Farber Cancer Institute between November 25, 1995, and April 25, 2011.
Necrotizing soft-tissue infection-associated in-hospital mortality.
Two hundred one patients were diagnosed as having NSTI. Forty-six were immunocompromised (as defined by corticosteroid use, active malignancy, receipt of chemotherapy or radiation therapy, diagnosis of human immunodeficiency virus or AIDS, or prior solid organ or bone marrow transplantation with receipt of chronic immunosuppression). At presentation, immunocompromised patients had lower systolic blood pressure (105 vs 112 mm Hg, P = .02), glucose level (124 vs 134 mg/dL, P = .03), and white blood cell count (6600/μL vs 17 200/μL, P < .001) compared with immunocompetent patients. Immunocompromised patients were less likely to have been transferred from another institution (26.1% vs 52.9%, P = .001), admitted to a surgical service (45.7% vs 83.2%, P < .001), or undergone surgical debridement on admission (4.3% vs 61.3%, P = .001). Time to diagnosis and time to first surgical procedure were delayed in immunocompromised patients (P < .001 and P = .001, respectively). Immunocompromised patients had higher NSTI-associated in-hospital mortality (39.1% vs 19.4%, P = .01).
AND RELEVANCE Immunocompromised status in patients with NSTI in this study is associated with delays in diagnosis and surgical treatment and with higher NSTI-associated in-hospital mortality. At presentation, immunocompromised patients may fail to exhibit typical clinical and laboratory signs of NSTI. Physicians caring for similar patient populations should maintain a heightened level of suspicion for NSTI and consider early surgical evaluation and treatment.
关于免疫功能低下的坏死性软组织感染(NSTI)患者的研究很少。
评估免疫功能低下状态对 NSTI 患者的影响。
在一家主要癌症中心的三级学术教学医院进行的单机构回顾性队列研究。
患有 NSTI 的患者。
1995 年 11 月 25 日至 2011 年 4 月 25 日在布莱根妇女医院和达纳法伯癌症研究所接受治疗。
与坏死性软组织感染相关的院内死亡率。
201 例患者被诊断为患有 NSTI。46 例为免疫功能低下(定义为使用皮质类固醇、活动性恶性肿瘤、接受化疗或放疗、诊断为人类免疫缺陷病毒或艾滋病、或既往接受过慢性免疫抑制的实体器官或骨髓移植)。就诊时,免疫功能低下的患者的收缩压(105 与 112mmHg,P=0.02)、血糖水平(124 与 134mg/dL,P=0.03)和白细胞计数(6600/μL 与 17200/μL,P<0.001)均低于免疫功能正常的患者。免疫功能低下的患者不太可能从其他机构转来(26.1%比 52.9%,P=0.001)、收入外科服务(45.7%比 83.2%,P<0.001)或入院时接受手术清创(4.3%比 61.3%,P=0.001)。免疫功能低下患者的诊断和首次手术时间延迟(P<0.001 和 P=0.001)。免疫功能低下的患者 NSTI 相关院内死亡率更高(39.1%比 19.4%,P=0.01)。
和相关性:本研究中 NSTI 患者的免疫功能低下状态与诊断和手术治疗的延迟以及 NSTI 相关院内死亡率较高有关。就诊时,免疫功能低下的患者可能无法表现出典型的 NSTI 临床和实验室征象。治疗类似患者群体的医生应保持高度警惕 NSTI,并考虑早期手术评估和治疗。